Atrial Fibrillation: A Real-Life Observational Study in the Québec Population

Canadian Journal of Cardiology

Volumn 27, Issue 6, 2011, Pages 794-799

  Guertin, Jason R ^a   Dorais, Marc ^b   Khairy, Paul ^c   Sauriol, Luc ^d   Matteau, Alexis ^a   Poulin, Frédéric ^c   Talajic, Mario ^c   Roy, Denis ^c   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b StatSciences Inc   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CANADA; CARDIAC PATIENT; COHORT ANALYSIS; DATA BASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTPATIENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PROGNOSIS; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 82155185279     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.03.009     Document Type: Article

References (32)

1. Bhatia A., Sra J. Atrial fibrillation: epidemiology, mechanisms and management. Indian Heart J 2000, 52:129-164.
2. Tsang T.S., Miyasaka Y., Barnes M.E., Gersh B.J. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 2005, 48:1-8.
3. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
4. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998, 32:695-703.
5. Bourassa M.G., Gurne O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993, 22:14A-19A.
6. Carson P.E., Johnson G.R., Dunkman W.B., Fletcher R.D., Farrell L., Cohn J.N. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation 1993, 87:VI102-VI110. The V-HeFT VA Cooperative Studies Group.
7. Kerr C.R., Roy D. Introduction: 2004 Canadian Cardiovascular Society Consensus Conference: Atrial Fibrillation. Can J Cardiol 2005, 21:9B-10B.
8. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
9. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
10. Roy D., Talajic M., Dubuc M., et al. Atrial fibrillation and congestive heart failure. Curr Opin Cardiol 2009, 24:29-34.
11. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
12. Hagens V.E., Ranchor A.V., Van Sonderen E., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004, 43:241-247.
13. Gronefeld G.C., Lilienthal J., Kuck K.H., Hohnloser S.H. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation: results from a prospective randomized study. Eur Heart J 2003, 24:1430-1436.
14. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690-1696.
15. Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004, 126:476-486.
16. Healey J.S., Parkash R., Pollak T., Tsang T., Dorian P. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: etiology and initial investigations. Can J Cardiol 2011, 27:31-36. CCS AF Guidelines Committee.
17. Murray S., Lazure P., Pullen C., Maltais P., Dorian P. Atrial fibrillation care: challenges in clinical practice and educational needs assessment. Can J Cardiol 2011, 27:97-103.
18. Wyse G. It's health care delivery, stupid: implementing the new CCS atrial fibrillation treatment guidelines. Can J Cardiol 2011, 27:14-18.
19. Dobrev D., Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010, 375:1212-1223.
20. Andrade J.G., Connolly S.J., Dorian P., et al. Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm 2010, 7:1171-1177.
21. Kerr C.R., Humphries K.H., Talajic M., et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005, 149:489-496.
22. Lelorier P., Humphries K.H., Krahn A., et al. Prognostic differences between atrial fibrillation and atrial flutter. Am J Cardiol 2004, 93:647-649.
23. Tamblyn R., Lavoie G., Petrella L., Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995, 48:999-1009.
24. Tamblyn R., Reid T., Mayo N., McLeod P., Churchill-Smith M. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000, 53:183-194.
25. Régie de l'assurance maladie du Québec Manuel des médecins omnipraticiens, Accessed August 15, 2009. http://www.ramq.gouv.qc.ca/fr/professionnels/manuels/100/000_complet_acte_omni.pdf.
26. Régie de l'assurance maladie du Québec Manuel des médecins spécialistes, Accessed August 15, 2009. http://www.ramq.gouv.qc.ca/fr/professionnels/manuels/150/000_complet_acte_spec.pdf.
27. Von Korff M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
28. Johnson R.E., Hornbrook M.C., Nichols G.A. Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol 1994, 47:1191-1199.
29. Singh B.N. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol 2008, 52:300-305.
30. Nattel S., Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006, 5:1034-1049.
31. Nattel S., Opie L.H. Controversies in atrial fibrillation. Lancet 2006, 367:262-272.
32. Riley M.J., Marrouche N.F. Ablation of atrial fibrillation. Curr Probl Cardiol 2006, 31:361-390.